摘要
目的 :评价国产双酒石酸长春瑞滨注射液 (以下称民诺宾 )对中晚期非小细胞肺癌及乳腺癌的疗效和不良反应 ,并与进口同类产品进行比较。方法 :全组非小细胞肺癌 (NSCLC)和乳腺癌 (BC) 14 9例 ,随机进入治疗组(国产民诺宾 )及对照组 (进口NVB) ,分别给予NP、NIP、NE(或NA)方案及单药化疗 ,两组所用药物及剂量、方法完全一致。结果 :治疗组与对照组治疗非小细胞肺癌有效率分别为 2 6 .7%和 2 8.6 % (P >0 .0 5 ) ,乳腺癌分别为 4 2 .9%和4 6 .7% (P >0 .0 5 ) ,毒性反应主要是骨髓抑制和消化道反应 ,治疗组与对照组WBC下降发生率分别为 87.5 %和90 % ,血小板下降分别为 4 0 %和 38% ,消化道反应分别为 82 .5 %和 78% ,组间无显著性差异。结论 :国产双酒石酸长春瑞滨注射液 (民诺宾 )疗效确切 。
Purpose:To observe the clinical response rate and side effects of vinorelbine (made in China) in comparison with Navelbine. Methods: A total of 149 patients with advanced non small cell lung cancer (NSCLC) and breast cancer (BC) were randomized into study group and control group, and treated with NP, NIP, NE (or NA) regimens, respectively. The same dosage was used in the two groups.Results:The response rate of study group and control group were 26.7% and 28.6% in NSCLC ( P >0.05), 42.9% and 46.7% in BC ( P >0.05), respectively. The major side effects were bone marrow suppression and gastrointestinal reaction. The response rate and toxicity were not statistically significant in the two groups. Conclusions:No difference could be found between the vinorelbine and NVB, and the side effects are tolerable.
出处
《中国癌症杂志》
CAS
CSCD
2002年第2期102-105,共4页
China Oncology
